Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Peptide mimic for influenza vaccination using nonnatural combinatorial chemistry.

Miles JJ, Tan MP, Dolton G, Edwards ES, Galloway SA, Laugel B, Clement M, Makinde J, Ladell K, Matthews KK, Watkins TS, Tungatt K, Wong Y, Lee HS, Clark RJ, Pentier JM, Attaf M, Lissina A, Ager A, Gallimore A, Rizkallah PJ, Gras S, Rossjohn J, Burrows SR, Cole DK, Price DA, Sewell AK.

J Clin Invest. 2018 Apr 2;128(4):1569-1580. doi: 10.1172/JCI91512. Epub 2018 Mar 12.

2.

Islet-reactive CD8+ T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors.

Culina S, Lalanne AI, Afonso G, Cerosaletti K, Pinto S, Sebastiani G, Kuranda K, Nigi L, Eugster A, Østerbye T, Maugein A, McLaren JE, Ladell K, Larger E, Beressi JP, Lissina A, Appay V, Davidson HW, Buus S, Price DA, Kuhn M, Bonifacio E, Battaglia M, Caillat-Zucman S, Dotta F, Scharfmann R, Kyewski B, Mallone R; ImMaDiab Study Group, Carel JC, Tubiana-Rufi N, Martinerie L, Poidvin A, JacqzAigrain E, Corvez L, Berruer V, Gautier JF, Baz B, Haddadi N, Andreelli F, Amouyal C, Jaqueminet S, Bourron O, Dasque E, Hartemann A, Lemoine-Yazigi A, Dubois-Laforgue D, Travert F, Feron M, Rolland P, Vignali V, Marre M, Chanson P, Briet C, Guillausseau PJ, Ait-Bachir L, Collet C, Beziaud F, Desforges-Bullet V, Petit-Aubert G, Christin-Maitre S, Fève B, Vatier C, Bourcigaux N, Lautridou C, Lahlou N, Bakouboula P, Elie C, Morel H, Treluyer JM, Gagnerault MC, Maillard C, Jones A.

Sci Immunol. 2018 Feb 2;3(20). pii: eaao4013. doi: 10.1126/sciimmunol.aao4013.

PMID:
29429978
3.

Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8+ TCR-Vβ+ expansions.

Lissina A, McLaren JE, Ilander M, Andersson EI, Lewis CS, Clement M, Herman A, Ladell K, Llewellyn-Lacey S, Miners KL, Gostick E, Melenhorst JJ, Barrett AJ, Price DA, Mustjoki S, Wooldridge L.

Sci Rep. 2018 Feb 7;8(1):2534. doi: 10.1038/s41598-017-18062-x.

4.

Targeted suppression of autoreactive CD8+ T-cell activation using blocking anti-CD8 antibodies.

Clement M, Pearson JA, Gras S, van den Berg HA, Lissina A, Llewellyn-Lacey S, Willis MD, Dockree T, McLaren JE, Ekeruche-Makinde J, Gostick E, Robertson NP, Rossjohn J, Burrows SR, Price DA, Wong FS, Peakman M, Skowera A, Wooldridge L.

Sci Rep. 2016 Oct 17;6:35332. doi: 10.1038/srep35332.

5.

TCR clonotypes: molecular determinants of T-cell efficacy against HIV.

Lissina A, Chakrabarti LA, Takiguchi M, Appay V.

Curr Opin Virol. 2016 Feb;16:77-85. doi: 10.1016/j.coviro.2016.01.017. Epub 2016 Feb 12. Review.

PMID:
26874617
6.

Fine-tuning of CD8(+) T-cell effector functions by targeting the 2B4-CD48 interaction.

Lissina A, Ambrozak DR, Boswell KL, Yang W, Boritz E, Wakabayashi Y, Iglesias MC, Hashimoto M, Takiguchi M, Haddad E, Douek DC, Zhu J, Koup RA, Yamamoto T, Appay V.

Immunol Cell Biol. 2016 Jul;94(6):583-92. doi: 10.1038/icb.2016.17. Epub 2016 Feb 10.

PMID:
26860368
7.

Identification of human viral protein-derived ligands recognized by individual MHCI-restricted T-cell receptors.

Szomolay B, Liu J, Brown PE, Miles JJ, Clement M, Llewellyn-Lacey S, Dolton G, Ekeruche-Makinde J, Lissina A, Schauenburg AJ, Sewell AK, Burrows SR, Roederer M, Price DA, Wooldridge L, van den Berg HA.

Immunol Cell Biol. 2016 Jul;94(6):573-82. doi: 10.1038/icb.2016.12. Epub 2016 Feb 5.

8.

Priming of Qualitatively Superior Human Effector CD8+ T Cells Using TLR8 Ligand Combined with FLT3 Ligand.

Lissina A, Briceño O, Afonso G, Larsen M, Gostick E, Price DA, Mallone R, Appay V.

J Immunol. 2016 Jan 1;196(1):256-263. doi: 10.4049/jimmunol.1501140. Epub 2015 Nov 25.

9.

Reduced naïve CD8(+) T-cell priming efficacy in elderly adults.

Briceño O, Lissina A, Wanke K, Afonso G, von Braun A, Ragon K, Miquel T, Gostick E, Papagno L, Stiasny K, Price DA, Mallone R, Sauce D, Karrer U, Appay V.

Aging Cell. 2016 Feb;15(1):14-21. doi: 10.1111/acel.12384. Epub 2015 Oct 15.

10.

Comparison of peptide-major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells.

Dolton G, Lissina A, Skowera A, Ladell K, Tungatt K, Jones E, Kronenberg-Versteeg D, Akpovwa H, Pentier JM, Holland CJ, Godkin AJ, Cole DK, Neller MA, Miles JJ, Price DA, Peakman M, Sewell AK.

Clin Exp Immunol. 2014 Jul;177(1):47-63. doi: 10.1111/cei.12339.

11.

The link between CD8⁺ T-cell antigen-sensitivity and HIV-suppressive capacity depends on HLA restriction, target epitope and viral isolate.

Lissina A, Fastenackels S, Inglesias MC, Ladell K, McLaren JE, Briceño O, Gostick E, Papagno L, Autran B, Sauce D, Price DA, Saez-Cirion A, Appay V.

AIDS. 2014 Feb 20;28(4):477-86. doi: 10.1097/QAD.0000000000000175.

12.

Application of magnetic field hyperthermia and superparamagnetic iron oxide nanoparticles to HIV-1-specific T-cell cytotoxicity.

Williams JP, Southern P, Lissina A, Christian HC, Sewell AK, Phillips R, Pankhurst Q, Frater J.

Int J Nanomedicine. 2013;8:2543-54. doi: 10.2147/IJN.S44013. Epub 2013 Jul 23.

13.

T-cell receptor-optimized peptide skewing of the T-cell repertoire can enhance antigen targeting.

Ekeruche-Makinde J, Clement M, Cole DK, Edwards ES, Ladell K, Miles JJ, Matthews KK, Fuller A, Lloyd KA, Madura F, Dolton GM, Pentier J, Lissina A, Gostick E, Baxter TK, Baker BM, Rizkallah PJ, Price DA, Wooldridge L, Sewell AK.

J Biol Chem. 2012 Oct 26;287(44):37269-81. doi: 10.1074/jbc.M112.386409. Epub 2012 Sep 5.

14.

Monoclonal TCR-redirected tumor cell killing.

Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, Gavarret J, Bianchi FC, Pumphrey NJ, Ladell K, Gostick E, Sewell AK, Lissin NM, Harwood NE, Molloy PE, Li Y, Cameron BJ, Sami M, Baston EE, Todorov PT, Paston SJ, Dennis RE, Harper JV, Dunn SM, Ashfield R, Johnson A, McGrath Y, Plesa G, June CH, Kalos M, Price DA, Vuidepot A, Williams DD, Sutton DH, Jakobsen BK.

Nat Med. 2012 Jun;18(6):980-7. doi: 10.1038/nm.2764.

PMID:
22561687
15.

MHC class I molecules with Superenhanced CD8 binding properties bypass the requirement for cognate TCR recognition and nonspecifically activate CTLs.

Wooldridge L, Clement M, Lissina A, Edwards ES, Ladell K, Ekeruche J, Hewitt RE, Laugel B, Gostick E, Cole DK, Debets R, Berrevoets C, Miles JJ, Burrows SR, Price DA, Sewell AK.

J Immunol. 2010 Apr 1;184(7):3357-66. doi: 10.4049/jimmunol.0902398. Epub 2010 Feb 26.

16.

Tricks with tetramers: how to get the most from multimeric peptide-MHC.

Wooldridge L, Lissina A, Cole DK, van den Berg HA, Price DA, Sewell AK.

Immunology. 2009 Feb;126(2):147-64. doi: 10.1111/j.1365-2567.2008.02848.x. Review. Erratum in: Immunology. 2009 Mar;126(3):447.

17.

Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers.

Lissina A, Ladell K, Skowera A, Clement M, Edwards E, Seggewiss R, van den Berg HA, Gostick E, Gallagher K, Jones E, Melenhorst JJ, Godkin AJ, Peakman M, Price DA, Sewell AK, Wooldridge L.

J Immunol Methods. 2009 Jan 1;340(1):11-24. doi: 10.1016/j.jim.2008.09.014. Epub 2008 Oct 16.

18.

Detection of low avidity CD8(+) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers.

Melenhorst JJ, Scheinberg P, Chattopadhyay PK, Lissina A, Gostick E, Cole DK, Wooldridge L, van den Berg HA, Bornstein E, Hensel NF, Douek DC, Roederer M, Sewell AK, Barrett AJ, Price DA.

J Immunol Methods. 2008 Sep 30;338(1-2):31-9. doi: 10.1016/j.jim.2008.07.008. Epub 2008 Jul 31.

19.

Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region.

Wooldridge L, Lissina A, Vernazza J, Gostick E, Laugel B, Hutchinson SL, Mirza F, Dunbar PR, Boulter JM, Glick M, Cerundolo V, van den Berg HA, Price DA, Sewell AK.

Eur J Immunol. 2007 May;37(5):1323-33.

20.

Functional and biophysical characterization of an HLA-A*6801-restricted HIV-specific T cell receptor.

Gostick E, Cole DK, Hutchinson SL, Wooldridge L, Tafuro S, Laugel B, Lissina A, Oxenius A, Boulter JM, Price DA, Sewell AK.

Eur J Immunol. 2007 Feb;37(2):479-86.

22.

Recognition of nonpeptide antigens by human V gamma 9V delta 2 T cells requires contact with cells of human origin.

Green AE, Lissina A, Hutchinson SL, Hewitt RE, Temple B, James D, Boulter JM, Price DA, Sewell AK.

Clin Exp Immunol. 2004 Jun;136(3):472-82.

23.
24.

High avidity antigen-specific CTL identified by CD8-independent tetramer staining.

Choi EM, Chen JL, Wooldridge L, Salio M, Lissina A, Lissin N, Hermans IF, Silk JD, Mirza F, Palmowski MJ, Dunbar PR, Jakobsen BK, Sewell AK, Cerundolo V.

J Immunol. 2003 Nov 15;171(10):5116-23.

Supplemental Content

Loading ...
Support Center